Evidence map›Paper›PMID 28732519›Full record

Trial reportTrials2017

Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial.

Joanne R Chalmers, Rachel H Haines, Eleanor J Mitchell, Kim S Thomas, Sara J Brown, Matthew Ridd, Sandra Lawton, Eric L Simpson, Michael J Cork, Tracey H Sach and 4 more

Open access · goldAbstract readMulticenter StudyPragmatic Clinical TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Skin care interventions in infants for preventing eczema and food allergy.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Skin care interventions in infants for preventing eczema and food allergy.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT.Health technology assessment (Winchester, England) · 2024
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Current Insights into Atopic March.Children (Basel, Switzerland) · 2021
    Review
  12. Review
  13. The Role of the Environment and Exposome in Atopic Dermatitis.Current treatment options in allergy · 2021
    Review
  14. Article
  15. Prevention of Atopic Dermatitis.Acta dermato-venereologica · 2020
    Review
  16. Article
  17. Halting the March: Primary Prevention of Atopic Dermatitis and Food Allergies.The journal of allergy and clinical immunology. In practice · 2020
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Joanne R ChalmersCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK. joanne.chalmers@nottingham.ac.uk.ORCID 0000-0002-2281-7367
Rachel H HainesNottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.
Eleanor J MitchellNottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.
Kim S ThomasCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
Sara J BrownSkin Research Group, School of Medicine, University of Dundee, Dundee, UK.
Matthew RiddSchool of Social and Community Medicine, University of Bristol, Bristol, UK.
Sandra LawtonThe Rotherham NHS Foundation Trust, Moorgate Road, Rotherham, UK.
Eric L SimpsonDepartment of Dermatology, Oregon Health and Science University, Portland, OR, USA.
Michael J CorkDepartment of Infection and Immunity, Sheffield, UK.
Tracey H SachHealth Economics Group, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.
Lucy E BradshawNottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.
Alan A MontgomeryNottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.
Robert J BoyleSection of Paediatrics, Imperial College London, Wright Fleming Building, London, UK.
Hywel C WilliamsCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
University of Nottingham · GBCentre for Immunity, Infection and Evolution · GBImperial College London · GBOregon Health & Science University · USThe Rotherham NHS Foundation Trust · GBUniversity of Bristol · GBUniversity of Dundee · GBUniversity of East Anglia · GB

Funding

Department of Health 12/67/12Department of Health PDF-2014-07-013Wellcome Trust
6 · The paper itself

Abstract

backgroundAtopic eczema (AE) is a common skin problem that impairs quality of life and is associated with the development of other atopic diseases including asthma, food allergy and allergic rhinitis. AE treatment is a significant cost burden for health care providers. The purpose of the trial is to investigate whether daily application of emollients for the first year of life can prevent AE developing in high-risk infants (first-degree relative with asthma, AE or allergic rhinitis).

methodsThis is a protocol for a pragmatic, two-arm, randomised controlled, multicentre trial. Up to 1400 term infants at high risk of developing AE will be recruited through the community, primary and secondary care in England. Participating families will be randomised in a 1:1 ratio to receive general infant skin-care advice, or general skin-care advice plus emollients with advice to apply daily to the infant for the first year of life. Families will not be blinded to treatment allocation. The primary outcome will be a blinded assessment of AE at 24 months of age using the UK Working Party Diagnostic Criteria for Atopic Eczema. Secondary outcomes are other definitions of AE, time to AE onset, severity of AE (EASI and POEM), presence of other allergic diseases including food allergy, asthma and hay fever, allergic sensitisation, quality of life, cost-effectiveness and safety of the emollients. Subgroup analyses are planned for the primary outcome according to filaggrin genotype and the number of first-degree relatives with AE and other atopic diseases. Families will be followed up by online and postal questionnaire at 3, 6, 12 and 18 months with a face-to-face visit at 24 months. Long-term follow-up until 60 months will be via annual questionnaires. DISCUSSION: This trial will demonstrate whether skin-barrier enhancement through daily emollient for the first year of life can prevent AE from developing in high-risk infants. If effective, this simple and cheap intervention has the potential to result in significant cost savings for health care providers throughout the world by preventing AE and possibly other associated allergic diseases.

trial registrationISRCTN registry; ID: ISRCTN21528841 . Registered on 25 July 2014.

Indexed as

Drug CostsAdministration, CutaneousChild, PreschoolClinical ProtocolsCommunity Health ServicesCost-Benefit AnalysisDermatitis, AtopicEmollientsEnglandFemaleFilaggrin ProteinsHumansInfantInfant, NewbornMaleOrganic ChemicalsDiprobaseDoublebaseEmollientsFilaggrin ProteinsFLG protein, humanOrganic ChemicalsAtopic dermatitisBarrier enhancementCore outcomesEczemaEmollientFilaggrinPreventionProtocolRandomised controlled trial

Identifiers

PMID28732519
PMCPMC5521124
OpenAlexW2737657439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.